Actively Recruiting
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-05-14
30
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase II, open-label, single-arm clinical study of nimotuzumab in combination with immune checkpoint inhibitors in patients with advanced liver cancer who have failed first-line therapy
CONDITIONS
Official Title
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of advanced hepatocellular carcinoma (HCC) confirmed by histology, cytology, or AASLD criteria
- Previous treatment with targeted, immune, or conventional therapy with progression or intolerance
- Child-Pugh liver function Grade A or B (7 points or less) within 7 days before first dose
- BCLC stage B or C, or CNLC stage III
- At least one measurable tumor lesion within 4 weeks before first dose per mRECIST v1.1
- Positive for EGFR and RAS wildtype status
You will not qualify if you...
- Diagnosis of hepatic cholangiocarcinoma, mixed cell carcinoma, or fibrolamellar cell carcinoma
- History of hepatic encephalopathy within 6 months before first dose
- Portal hypertension with red signs or high bleeding risk; esophageal or gastric variceal bleeding within 6 months before first dose
- Symptomatic brain or meningeal metastases unless treated >3 months ago, stable without progression on imaging for 4 weeks before treatment, and stable clinical symptoms
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Actively Recruiting
Research Team
C
Chuntao Gao, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here